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ABSTRACT
Objective: Coronary heart disease (CHD) is associated with a large
burden of disease in Ireland and is responsible for more than 6000 deaths
annually. This study examined the cost-effectiveness of speciﬁc CHD treat-
ments in Ireland.
Methods: Irish epidemiological data on patient numbers and median sur-
vival in speciﬁc groups, plus the uptake, effectiveness, and costs of speciﬁc
interventions, all stratiﬁed by age and sex, were incorporated into a
previously validated CHD mortality model, the IMPACT model. This
model calculates the number of life-years gained (LYGs) by speciﬁc cardi-
ology interventions to generate incremental cost-effectiveness ratios
(ICERs) per LYG for each intervention.
Results: In 2000, medical and surgical treatments together prevented or
postponed approximately 1885 CHD deaths in patients aged 25 to 84
years, and thus generated approximately 14,505 extra life-years
(minimum 7270, maximum 22,475). In general, all the cardiac interven-
tions investigated were highly cost-effective in the Irish setting. Aspirin,
beta-blockers, ACE inhibitors, spironolactone, and warfarin for speciﬁc
conditions were the most cost-effective interventions (<€3000/LYG), fol-
lowed by the statins for secondary prevention (<€6500/LYG). Revascular-
ization for chronic angina and primary angioplasty for myocardial
infarction, although still cost-effective, had the highest ICER (between
€12,000 and €20,000/LYG).
Conclusions: Using a comprehensive standardized methodology, cost-
effectiveness ratios in this study clearly favored simple medical treatments
for myocardial infarction, secondary prevention, angina, and heart failure.
Keywords: CHD mortality, heart disease, IMPACT model, Ireland.
Introduction
Expenditure on health care in Ireland has increased from approxi-
mately €3.7 billion in 1997 tomore than €11.3 billion in 2005 [1].
Not surprisingly, the issue of value for money arises and a number
of reports including the 2003 Commission on Financial Manage-
ment and Control Systems in the Health Service (Brennan report)
recommended that a review be undertaken to ensure such expen-
diture provides good value for money [2]. New technologies
including, but not limited to, pharmaceuticals are increasingly
being subjected to Health Technology Assessment (HTA). The
Irish National Health Strategy 2001 proposed a system of HTA
which would enable the health-care system to: 1) introduce tech-
nologies speedily with proven, signiﬁcant health beneﬁts; 2)
prevent the introduction of technologies which fail to meet
requirements of evidence-based analysis; and 3) continuously
monitor the effect of technologies after their introduction [3].
The 2006 agreement between the Irish Pharmaceutical
Healthcare Association (IPHA) and the Health Service Executive
(HSE) facilitated the introduction of HTA. The agreement con-
ﬁrms that “the HSE reserves the right to assess new and existing
technologies (pharmaceuticals, diagnostics, and devices) that
may have a high unit cost or a signiﬁcant budget impact on the
Irish health care system” [4]. Cardiovascular medications
accounted for approximately 25% (€318.5 million) of spending
under the Community Drugs Schemes in 2005. This is not sur-
prising as coronary heart disease (CHD) remains a leading cause
of death and disability in Ireland, and mortality rates are still
among the highest in Europe. Nevertheless, CHD mortality rates
have fallen since the mid-1980s with steeper falls in younger age
groups. Between 1985 and 2000 mortality rates in Ireland fell by
47% in those aged 25 to 84 years. Some 43.6% of the observed
decrease in mortality was attributed to treatment effects [5]. In
this study we determine the cost-effectiveness of the principal
CHD treatments over the 10-year period between 2000 and
2010.
Methods
We identiﬁed and analyzed the following conditions: acute myo-
cardial infarction (AMI), secondary prevention after AMI or
revascularization, unstable angina, chronic angina, heart failure
in hospital and in the community, plus primary prevention using
statins (HMG-CoA reductase inhibitor). The speciﬁc medical and
surgical therapies considered included aspirin, thrombolysis,
beta-blockers, ACE inhibitors, statins, cardiac rehabilitation,
warfarin, heparin, glycoprotein IIb/IIIa inhibitors, coronary
artery bypass graft (CABG) surgery, and angioplasty.
The IMPACT CHD Mortality Model
This previously validated cell-based IMPACT CHD mortality
model has been described in detail elsewhere [6]. In brief, the
model utilizes a very large Microsoft Excel spreadsheet to inte-
grate data on: CHD patient numbers, uptake of speciﬁc medical
and surgical treatments, effectiveness of speciﬁc treatments, and
median survival in patients with and without CHD. It includes
data for men and women aged 25 to 84 years. The model was
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developed using extensive data describing the population in
Ireland for the year 2000 [5]. The complete IMPACT CHD
mortality model also includes the mortality consequences of
population trends in major risk factors; however, these were not
the focus of this analysis. The effectiveness estimates for each
therapy were based on recent meta-analyses and large random-
ized controlled trials. The complete list of such trials and meta-
analyses, the base-case effectiveness estimates, and all the other
underlying assumptions have been published previously [6–9]
and can also be accessed on the IMPACT website (http://www.
liv.ac.uk/PublicHealth/sc/bua/impact.html), as well as detailed
in appendices I to III (http://www.ispor.org/publications/value/
ViHsupplementary.asp).
Estimating the Number of Deaths Prevented or
Postponed (DPPs) in Ireland in 2000
The number of CHD deaths prevented or postponed by each
treatment group was based on the relative mortality reduction
reported in published trials and meta-analyses applied to the case
fatality observed in unselected patient cohorts. This was calcu-
lated based on the product of four variables: number of eligible
patients for each age–sex-speciﬁc cardiology intervention (e.g.,
number of AMI patients for secondary prevention following
AMI), treatment uptake levels, compliance rate (patients’ adher-
ence), and absolute risk reduction due to the particular interven-
tion (which is a product of relative risk and case-fatality rates).
To avoid double counting, adjustments were ﬁrst made for over-
laps between different treatment groups, by subtracting the over-
lapping subgroup from the main group. For instance, the
postmyocardial infarct (MI) survivors total was reduced by 25%,
to allow for those post-MI patients who subsequently developed
heart failure.
Sources of the Irish data and detailed technical appendices can
be found on the IMPACT website (http://www.liv.ac.uk/
PublicHealth/sc/bua/impact.html). The website also provides
details on operational deﬁnitions of the six cardiovascular risk
factors studied, on the polypharmacy issues, how double counting
of patients are adjusted for, as well as an in-depth calculation of
the numbers of DPPs, with examples.
Median Survival Data
For each treatment category, median survival was obtained
from the best available population-based data. Estimates of sur-
vival after coronary surgery were obtained from the Irish
Cardiac Surgery Register [10] plus a recent cohort study in
Scotland [11]. Angioplasty for angina was assumed to have a
similar survival beneﬁt [12]. Because other survival data in
Ireland are limited [13], most age-speciﬁc median survival data
were obtained from large cohort studies of unselected patients
with AMI or heart failure in the United Kingdom [14,15]. The
data for Ireland are likely to be very similar to the UK pattern,
as Ireland has followed similar CHD mortality and treatment
trends since the mid-1980s. Median survival estimates for
patients treated for hypertension were based on the Glasgow
Blood Pressure Clinic cohort [16].
The following assumptions were also made
1. In patients with recognized CHD, median survival was
assumed to be very similar to that in age-matched myocar-
dial infarction survivors.
2. In asymptomatic individuals, median survival was based on
age-speciﬁc life expectancy for the general population (cal-
culated from Irish life-tables) [17].
3. In subjects with symptomatic but unrecognized CHD, the
median survival was assumed to lie midway between the
values for myocardial infarction survivors and the general
population.
4. The IMPACT CHD mortality model default assumptions
for compliance were 100% in hospital patients, 70% in
symptomatic community patients, and 50% in asymptom-
atic community patients [18]. In short, we looked at
patients’ adherence to therapeutically effective levels of
medication for the general calculation of the number of
DPPs due to treatments. All of these assumptions were
tested in subsequent robust sensitivity analyses.
Estimation of Life-Years Gained (LYGs)
The number of LYGs in 2000 for each treatment category and for
each risk factor change was estimated across sex and age groups.
Each LYG estimate was calculated as the number of DPPs in
2000 from the IMPACT CHD mortality model, multiplied by the
age-speciﬁc median survival for the age–sex group [5,19]. The
LYG total was then obtained by summing individual LYG values
across every age and sex category for each speciﬁc treatment
group. Our LYG estimates were not explicitly adjusted for the
inﬂuence of other competing causes of mortality such as cancer.
Nevertheless, these are generally modest, amounting to less than
one extra year of life [20,21]. Interaction was not tested in this
model.
For this study, the 1985/2000 Irish IMPACT CHD mortality
model was extended to follow each cohort of patients who
received speciﬁc treatments for up to 10 years, over the time
period 2000 to 2010. For example, we have estimated DPPs for
a particular age group for a speciﬁc intervention in 2000, and
then based on the case-fatality rates and treatment efﬁcacy for
this particular treatment-case group, the incremental DPPs
without and with treatments were calculated. The difference of
the estimated DPPs between treatment and without treatment
gives the incremental DPPs, and when these incremental DPPs
were discounted using a discount rate of 3.5% from year 1,
namely, from 2001 onward, the discounted DPPs are calculated
yearly for each treatment-case group. The details are explained in
the tabular example attached (Tables 1 and 2).
Furthermore, the median survival for a speciﬁc treatment-pair
group was estimated, as shown in the tabular example attached
herewith. Finally, the discounted LYG for each treatment-case
group is the summation of the yearly products of the median
survival and the discounted DPPs for the 10-year period. The
ratios of the calculated cost and the estimated LYG were then
used in cost-effectiveness ratio calculations. Results were then
stratiﬁed by age and sex. The detailed results for men are pre-
sented; the results for women were very similar and are detailed
on the website.
The objective of this study was to compare all available
treatments in CHD for a given year (2000) to analyze the efﬁ-
ciency of cost allocation in the health system. In this analysis, we
aimed to provide a snap shot of the health system for the deﬁned
period (and on the basis of real prescriptions), and we did not
further analyze the prescription trends for each treatment–
disease pair. Therefore, we compared the effectiveness of the
intervention to another treatment or the best available treatment.
In the few remaining cases, for example, cardiac rehabilitation, it
was treatment versus no treatment.
Costing Methodology
Unit costs for health technologies were estimated using the Irish
case-mix model of Diagnostic-Related Groups for inpatient sur-
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gical procedures such as angioplasty and CABG. This case-mix
model uses Hospital In-Patient Enquiry data from the Economic
and Social Research Institute covering more than 90% of public
hospitals and a few private and voluntary hospitals across
Ireland [22]. The costs for the year 2001 were used. Such an
analysis also includes other costs (dispensing costs, hospital
costs, overhead costs, etc.) for medical procedures.
For drugs, the unit costs were derived from actual prescribing
data available from the HSE-Primary care reimbursement ser-
vices (PCRS, formerly General Medical Services [GMS] scheme).
This pharmacy claims database is a major resource of drug
prescription data in Ireland. The HSE-PCRS population coverage
is approximately 30%; however, it accounts for more than 65%
of all prescribing. The WHO Anatomical Therapeutic Chemical
classiﬁcation was used for classifying drugs, for example, statins
(C10AA) and the four main types of statins prescribed to
HSE-PCRS patients in 2000: atorvastatin (C10AA05), ﬂuvas-
tatin (C10AA04), pravastatin (C10AA03), and simvastatin
(C10AA01). The GMS prescribing database was used to identify
the common drugs within each of the drug classes (statins, ACE
inhibitors, beta-blockers, etc.) and associated formulations pre-
scribed (tablets, capsules, etc.). The deﬁned daily dose (DDD),
the average recommended daily adult dose, of each of the drug
classes was calculated. A weight based on the percentage distri-
bution of DDDs for individual drugs within a drug class was then
calculated. Individual drug acquisition ingredient costs were
obtained from the Irish Monthly Index of Medical Specialties
(July 2000). The total ingredient cost incurred for each drug class
was then calculated by multiplying the annual cost of each drug
by the weight for that drug and then by summing over all drugs
within the drug class. This was repeated for each of the drug
classes.
Cost of cardiac rehabilitation was taken from the published
literature. Gray et al. [23] in 1997 showed that the cost of
cardiac rehabilitation for the British setting is £370, which was
converted to Euros for the Irish setting. In addition, a recent
study by Beswick et al. published in 2004 [24] did not show
much change in the costs of cardiac rehab since 1997, ranging
from £350 to £490.
Only drug costs and intervention costs were included in this
analysis. Incremental cost-effectiveness ratios (ICERs) were
calculated in terms of incremental cost per additional LYG.
Costs, LYGs, and the numbers of DPPs for each age group were
discounted on an annual incremental basis for the 10-year
study period, using a discount rate of 3.5%. The methods
used here are similar to those explained for England and Wales
[25].
Time Frame
All costs and effects were estimated for 10-year age bands and for
both men and women. The very small number of patients aged
below 35 years was excluded from the analysis, as were those
aged more than 85 years [5]. Interventions for AMI and acute
coronary syndrome were evaluated over a 1-year scenario.
Cardiac rehabilitation beneﬁts were assumed to last for 2 years
[26].
Cost-effectiveness ratios were calculated on the basis of a
10-year time horizon for continuous drug interventions in all
chronic conditions except heart failure. Given the severely
reduced life expectancy in heart failure, costs and beneﬁts were
calculated over 2 years for patients admitted to hospital, and
over 5 years for heart failure patients treated only in the
community [27].
Table 1 Calculations of incremental discounted DPPs (CHD deaths prevented/postponed)
Year C/F C/E DPPs without Rx (Rx-) DPPs with Rx (Rx+) Estimated DPPs Discounted DPPs
2000 x y Rx-2000 [5,19] Rx+2000 [5,19] Rx+2000 - Rx-2000 0
2001 x y Rx-2000 - (Rx-2000 * x) Rx+2000 - (Rx+2000 * x) (1 - y) Rx+2001 - Rx-2001 DPP2001 -Discounted Yr1
2002 x y Rx-2001 - (Rx-2001 * x) Rx+2001 - (Rx+2001 * x) (1 - y) Rx+2002 - Rx-2002 DPP2002 -Discounted Yr2
2003 x y Rx-2002 - (Rx-2002 * x) Rx+2002 - (Rx+2002 * x) (1 - y) Rx+2003 - Rx-2003 DPP2003 -Discounted Yr3
2004 x y Rx-2003 - (Rx-2003 * x) Rx+2003 - (Rx+2003 * x) (1 - y) Rx+2004 - Rx-2004 DPP2004 -Discounted Yr4
2005 x y Rx-2004 - (Rx-2004 * x) Rx+2004 - (Rx+2004 * x) (1 - y) Rx+2005 - Rx-2005 DPP2005 -Discounted Yr5
2006 x y Rx-2005 - (Rx-2005 * x) Rx+2005 - (Rx+2005 * x) (1 - y) Rx+2006 - Rx-2006 DPP2006 -Discounted Yr6
2007 x y Rx-2006 - (Rx-2006 * x) Rx+2006 - (Rx+2006 * x) (1 - y) Rx+2007 - Rx-2007 DPP2007 -Discounted Yr7
2008 x y Rx-2007 - (Rx-2007 * x) Rx+2007 - (Rx+2007 * x) (1 - y) Rx+2008 - Rx-2008 DPP2008 -Discounted Yr8
2009 x y Rx-2008 - (Rx-2008 * x) Rx+2008 - (Rx+2008 * x) (1 - y) Rx+2009 - Rx-2009 DPP2009 -Discounted Yr9
2010 x y Rx-2009 - (Rx-2009 * x) Rx+2009 - (Rx+2009 * x) (1 - y) Rx+2010 - Rx-2010 DPP2010 -Discounted Yr10
We assumed DPPs with and without treatment for the baseline year (2000) to be equal for comparisons, and the values are derived from the original Irish IMPACT Model estimation [5,19].
C/E: clinical effectiveness of individual treatment categories (reported as relative risk), and the values are all given in Appendix III; C/F: case fatality; CHD, coronary heart disease; DPP, death
prevented or postponed.
Table 2 Calculations of incremental discounted LYGs
Year Discounted DPPs Median survival (MS) LYG =Discounted DPPs * MS
2001 DPP2001 -Discounted Yr1 MS2005 + (MS2005 -MS2010) * 4/5 DPP2001 * MS2001
2002 DPP2002 -Discounted Yr2 MS2005 + (MS2005 -MS2010) * 3/5 DPP2002 * MS2002
2003 DPP2003 -Discounted Yr3 MS2005 + (MS2005 -MS2010) * 2/5 DPP2003 * MS2003
2004 DPP2004 -Discounted Yr4 MS2005 + (MS2005 -MS2010) * 1/5 DPP2004 * MS2004
2005 DPP2005 -Discounted Yr5 MS2005 DPP2005 * MS2005
2006 DPP2006 -Discounted Yr6 MS2005 - (MS2005 -MS2010) * 1/5 DPP2006 * MS2006
2007 DPP2007 -Discounted Yr7 MS2006 - (MS2005 -MS2010) * 1/5 DPP2007 * MS2007
2008 DPP2008 -Discounted Yr8 MS2007 - (MS2005 -MS2010) * 1/5 DPP2008 * MS2008
2009 DPP2009 -Discounted Yr9 MS2008 - (MS2005 -MS2010) * 1/5 DPP2009 * MS2009
2010 DPP2010 -Discounted Yr10 (MS2005 +MS2005 of immediate next age group)/2 DPP2010 * MS2010
Discounted LYG = sum (LYG2001 + LYG2002 +. . . . . . LYG2010).
DPP, death prevented or postponed; LYG, life-year gained.
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Sensitivity Analyses
Sensitivity analyses were performed using multiway analysis of
extremes method [28]. This systematically addressed the uncer-
tainties surrounding the key variables (treatment costs, patient
numbers, treatment uptake, treatment efﬁciency, median sur-
vival, and the overlap between different treatment categories).
Base-case ICERs were calculated using the best estimates for
costs and effectiveness. In other words, the minimum and
maximum estimates of LYGs were applied to the reference cost in
sensitivity analyses. Minimum and maximum mortality reduc-
tions were generated using 95% conﬁdence intervals from meta-
analyses for treatment efﬁcacy, and minimum and maximum
plausible values for patient numbers, treatment and uptake and
adherence. This method does not involve any probabilistic inter-
pretation as in conﬁdence interval estimation, nor does this
contain details on the statistical variations around the estimates.
Illustrative examples of speciﬁc analyses and calculations are
shown in the appendices of the recent England and Wales model
publication [6], and also on the IMPACT website.
Results
Speciﬁc medical and surgical treatments for CHD patients pre-
vented or postponed approximately 1885 deaths in Ireland in the
year 2000 (Table 3). The combined effect of all the relevant
treatments generated a total of approximately 14,505 additional
life-years (minimum estimate 7270, maximum estimate 22,470).
The largest contributions came from secondary prevention fol-
lowing myocardial infarction (22%), secondary prevention fol-
lowing revascularization (20%), and heart failure (10%). CABG
surgery and angioplasty procedures in angina patients together
accounted for approximately 18% of the total discounted LYG.
In general, all the cardiac interventions in the Irish settings
could be considered cost-effective (Table 4). Nevertheless,
aspirin, beta-blockers, ACE inhibitors, spironolactone, and war-
farin for speciﬁc disease conditions offered the best value for
money (<€3000/LYG). Statins for secondary prevention were
also very cost-effective (<€7000/LYG). Revascularization for
chronic angina (CABG surgery €12,968 and angioplasty
€14,864/LYG) and the use of statins in primary prevention were
relatively less cost-effective (€11,442/LYG). The overall cost-
effectiveness of primary angioplasty for myocardial infarction
was €19,206/LYG reaching to €26,006/LYG in men aged 75 to
84 years (Table 4). In Table 4, there was an age gradient across
all the interventions studied. For example, primary angioplasty
for AMI was least cost-effective among the elderly (75–84 years)
as compared to the younger populations. A similar pattern was
observed for statins in secondary prevention and IIb/IIIa inhibi-
tors for unstable angina.
Variation of the parameters in the model in a series of mul-
tiway sensitivity analyses is presented which does not show sub-
stantial change to the cost/LYG ratios (Table 5).
Discussion
This study demonstrates the cost-effectiveness of a wide range
of cardiac interventions in the Irish health-care setting
(<€20,000/LYG). Medications such as aspirin, beta-blockers,
ACE inhibitors, spironolactone, and warfarin offered the best
value for money. A recent study indicated that just less than
50% of the reduction in CHD mortality in Ireland could be
attributed to medical treatments, particularly secondary preven-
tative therapies and treatment of heart failure [5]. Although
there is no ﬁxed threshold for cost-effectiveness in Ireland, the
ICERs reported in this study are comparable to that of a pre-
vious study on statins for primary prevention of cardiovascular
events in Ireland (ICERs range from €17,900 to €33,800/LYG)
[29]. This study conﬁrms the cost-effectiveness of statins in the
secondary prevention of CHD with ICERs varying from €4340
to €6982/LYG. These ﬁgures are slightly higher than a previous
study where the cost-effectiveness of statin therapy in secondary
prevention ranged from €1272 to €3900 per quality-adjusted
life-year (QALY). The studies are not comparable as the
outcome measure differs between the two studies [30]. The dif-
ference may be explained, in part, because of differing meth-
odologies particularly the duration of therapy incorporated into
the economic models. Not surprisingly, the ICERs for statin
therapy in primary prevention were higher as the risk of a coro-
nary event is lower and ranged from €5,888 to €18,170/LYG,
similar to another study investigating the cost-effectiveness of
statins for the primary prevention of CHD in Ireland [29].
Although generic statin prescribing was included in the costs,
prescribing is very low in Ireland (approximately 7%) and
would therefore not have had a large effect.
The role of beta-blockers in the management of patients with
heart failure is now well established and a previous study indi-
cated the cost-effectiveness of carvedilol at €1560/LYG [31]. In
our study the cost-effectiveness of beta-blockers for the treatment
of heart failure ranged from €483 to €558/LYG. Spironolactone
Table 3 Number of LYGs by the medical and surgical treatments of coronary heart disease in Ireland in 2000
Intervention Patients eligible
Number of deaths
prevented/postponed LYGs Best estimate % of total LYGs
Acute myocardial infarction 3,970 166 1,086 7.5
Secondary prevention
Post myocardial infarction 37,245 580 3,180 21.9
Post coronary surgery or angioplasty 24,438 229 2,912 20.1
Angina
CABG surgery 18,990 144 2,054 14.2
Angioplasty 11,023 45 631 4.3
Unstable angina 2,432 33 208 1.4
Angina in community 100,598 241 2,061 14.2
Heart failure
Hospital treatment 1,715 150 237 1.6
Community treatment 12,940 190 1,219 8.4
Hypertension treatments 705,648 59 545 3.8
Statins for primary prevention 915,169 46 371 2.6
Total treatment effects in 2000 1,883 14,504 100
CABG, coronary artery bypass graft; LYG, life-year gained.
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has also been shown to be cost-effective in the treatment of severe
heart failure in previous studies and was conﬁrmed here with
ICERs ranging from €999 to €1156/LYG in the community
setting.
In the United Kingdom, the benchmark for maximum accept-
able cost-effectiveness ratios has been set by the National Insti-
tute for Clinical Excellence (NICE) appraisals consistently
around £20,000 to £30,000/QALY. This ﬁgure is around
€45,000/QALY if converted to euros in Ireland. Although no
formal benchmarks have been set for cost per LYG, similar values
are also used for cost per LYG (these would be slightly lower,
because quality-of-life weights are always much lower than 1.0 in
CHD patients, often just 0.6 or 0.7).
Limitations of This Study
The primary aimof this articlewas to compare a range of therapies
using a standard methodology. This study therefore focused on
average net treatment costs for each LYG. It did not explicitly
capture reductions in admissions, follow-up visits, costs associ-
ated with adverse events, or potential costs avoided (such as
further infarcts, or further revascularization). Employing more
complex modeling techniques, while theoretically desirable, was
not feasible. We did not attempt to perform a cost-effectiveness
analysis of individual technologies, for example, using a Markov
modelingmethodology. Other evidence suggests that the inclusion
of long-term cost consequences in other studies may make a
surprisingly small difference [32]. Each relative risk value of
treatment in the model was based on a meta-analysis comparison
with placebo, or an older therapy. The perfect economic analysis
would prefer a mixed treatment comparison to establish a
common baseline. While not ideal, the IMPACT model produced
an approximation to this, by recognizing that most patients in
most groups were receiving multiple therapies.
New technologies including pharmaceuticals are increasingly
being subjected to HTA in an attempt to demonstrate value for
money. Pharmacoeconomic assessment is now a requirement in
several European Member States including Finland, The Nether-
lands, Norway, and Sweden before reimbursement decisions. In
Portugal and Denmark cost-effectiveness data are incorporated
Table 4 Cost-effectiveness ratios (€/LYG) for all treatments, grouped
by 10-year age bands in Ireland, 2000 to 2010
Age group (year) All 45–54 55–64 65–74 75–84
Acute myocardial
infarction
Cardiopulmonary
resuscitation
303 159 293 1,040 1,571
Thrombolysis 2,164 2,192 2,048 1,979 2,980
Primary angioplasty 19,206 19,129 17,870 17,272 26,006
ACE inhibitors 2,698 3,430 2,687 2,497 2,407
Secondary prevention
post-acute
myocardial
infarction
Aspirin 1,144 1,027 1,126 1,339 1,674
Beta-blockers 1,077 974 1,067 1,267 1,576
ACE inhibitors 2,295 2,074 2,272 2,698 3,356
Statins 4,741 4,340 4,753 5,635 6,982
Warfarin 1,392 1,245 1,364 1,623 2,029
Cardiac
rehabilitation
7,679 6,886 7,543 8,946 11,100
Secondary prevention
post-CABG
surgery or
angioplasty
Aspirin 755 743 737 686 848
Beta-blockers 715 706 698 650 804
ACE inhibitors 1,523 1,504 1,487 1,384 1,711
Statins 3,193 3,147 3,109 2,894 3,578
Warfarin 916 903 893 831 1,028
Cardiac
rehabilitation
5,029 4,993 4,934 4,593 5,679
Revascularization
CABG surgery 12,968 10,804 11,759 13,059 20,973
Angioplasty 14,864 13,555 14,219 15,712 19,430
Community angina
Aspirin 1,695 1,786 1,541 1,494 1,807
Statins 6,318 8,026 5,684 4,163 5,834
Unstable angina
Aspirin 862 757 883 1,080 1,161
IIb/IIIa inhibitors 6,394 5,904 6,887 8,438 9,085
Heart failure (severe,
i.e., those
admitted to
hospital)
ACE inhibitors 3,922 2,648 3,575 4,402 5,374
Beta-blockers 1,227 859 1,138 1,361 1,627
Spironolactone 2,750 1,787 2,394 2,917 3,533
Aspirin 2,341 1,509 2,078 2,638 3,291
Statins 8,854 6,233 8,368 10,223 12,406
Heart failure
(community
patients)
ACE inhibitors 1,668 1,466 1,697 1,699 1,673
Beta-blockers 548 483 558 558 550
Spironolactone 1,135 999 1,155 1,156 1,139
Aspirin 941 822 955 957 940
Statins 3,941 3,465 4,008 4,013 3,953
Primary prevention
Statins 11,442 18,170 10,565 6,763 5,888
Hypertension 351 711 430 250 160
CABG, coronary artery bypass graft; LYG, life-year gained.
Table 5 Sensitivity analysis of cost-effectiveness ratios (€/LYG) for all
cardiology treatments in Ireland, 2000 to 2010
Min Best Max
AMI Hospital CPR 205 303 410
PTCA 11,550 19,206 23,085
Thrombolysis 1,316 2,164 2,629
ACE inhibitors 1,613 2,698 3,223
Post-MI Aspirin 687 1,144 3,413
Beta-blockers 647 1,077 3,201
ACE inhibitors 1,385 2,295 6,683
Statins 2,881 4,741 13,383
Warfarin 837 1,392 4,125
Post-revascularization Aspirin 671 755 861
Beta-blockers 637 715 815
ACE inhibitors 1,356 1,523 1,736
Statins 2,848 3,193 3,632
Warfarin 816 916 1,046
Rehab 4,498 5,029 5,703
Revascularization CABG surgery 9,801 12,968 14,815
Angioplasty 14,298 14,864 20,489
Community angina Statins 5,308 6,317 7,803
Aspirin 1,196 1,695 1,818
Unstable angina Aspirin 362 862 559
Hospital HF ACE inhibitors 2,761 3,922 6,768
Beta-blockers 874 1,227 2,056
Aspirin 1,624 2,341 4,191
Spironolactone 1,931 2,750 4,773
Statins 6,272 8,854 15,050
Community HF ACE inhibitors 1,343 1,668 2,199
Beta-blockers 442 548 718
Aspirin 755 941 1,248
Spironolactone 915 1,135 1,494
Statins 3,177 3,941 5,191
Primary prevention Statins 6,989 11,442 13,880
Hypertension 221 351 434
AMI, acute myocardial infarction;CABG, coronary artery bypass graft;CPR, cardiopulmonary
resuscitation;HF, heart failure; LYG, life-year gained;MI,myocardial infarct; PTCA, angioplasty.
14 Bennett et al.
into the reimbursement process and the NICE evaluates the
cost-effectiveness of medicines for the National Health Services
(NHS) in Britain [4].
This study compares the cost-effectiveness of a wide range of
cardiovascular therapies in the Irish health-care setting. The
majority of the data included covered the entire adult population
in Ireland and therefore avoids sampling errors. The IMPACT/
CHD mortality model methodology has been replicated in a
number of countries including Ireland. The demand for such
cost-effectiveness data in the Irish health-care setting is set to
increase following recent developments, which include the IPHA/
HSE agreement, the strategy for cancer control in Ireland which
recommends a cancer HTA panel with an emphasis on diagnostic
and therapeutic technologies, and the strategy for science, tech-
nology, and innovation.
HTA is one of the main remits of the new Health Information
and Quality Authority (HIQA). It is envisaged that HIQA will
lead the system-wide HTA process in Ireland through the forma-
tion of a HTA program board, which will determine the choice of
HTA with each appraisal being overseen by a HTA reference
group. It is envisaged that HIQA will play a central role in
developing health and personal social services in Ireland and will
help ensure that quality of care is promoted throughout the
health system and that patients receive the best possible out-
comes within available resources.
Supplementary materials for this article can be found at: http://www.
ispor.org/publications/value/ViHsupplementary.asp
Source of ﬁnancial support: Irish Heart Foundation.
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